Pfizer settled with three generic challengers and pushed Vyndamax competition to 2031. No court ruled its patents valid.

By ··1 min read·2 sources

The settlements are private, their terms are undisclosed, and patients keep paying the branded price for up to two more years.

On April 28, 2026, Pfizer announced settlements with Dexcel Pharma, Hikma and Cipla in Delaware patent cases over Vyndamax. It said the deals extend the drug's effective U.S. patent expiry to June 1, 2031, subject to other litigation. Pfizer had expected U.S. revenue to fall sharply from 2029; it now expects revenue to hold roughly stable through mid-2031. A case against Apotex is still pending.

No judge decided whether the patents are valid. The challengers withdrew, and Pfizer gave no financial terms. The public cannot tell what, if anything, the generic firms received for agreeing to wait. That is the governance gap: a private contract moved the date of competition for a $6 billion drug, and the people paying for it cannot read it.

The stake is plain from this year's data. ESC 2026 left doubts over whether silencers add enough to stabilizers, after AstraZeneca and Ionis's Wainua failed its primary endpoint and Alnylam's Amvuttra showed a modest benefit. The market is already shifting toward stabilizer pills: Alnylam cut its Amvuttra forecast in July and its shares fell 29%. Pfizer has ensured its pill faces no generic until 2031.

California's transparency rules make manufacturers report list-price increases. They do not reach settlement terms. The settlements protect revenue. They are not evidence that the patents would have survived trial.

Sources

  1. pfizer.com · pfizer.com/news/press-release/press-release-detail/pfizer-reaches-three-settlement-agreeme…
  2. eureporter.co · eureporter.co/health/2026/09/14/attr-cm-takes-center-stage-at-esc-2026/

Cite this report

The Precedent. "Pfizer settled with three generic challengers and pushed Vyndamax competition to 2031. No court ruled its patents valid.." September 16, 2026. https://theprecedent.org/article/pfizer-settled-with-three-generic-challengers-and-pushed-vyndamax-competition-to

Companies in this report